ACTUATE THERAPEUTICS INC (ACTU) Stock Overview
USA - NASDAQ:ACTU - US0050831009 - Common Stock
ACTU Key Statistics, Chart & Performance
The current stock price of ACTU is 6.71 USD. In the past month the price decreased by -17.39%. In the past year, price increased by 6.06%.
ACTU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.71 | 387.37B | ||
| AMGN | AMGEN INC | 12.45 | 146.24B | ||
| GILD | GILEAD SCIENCES INC | 14.35 | 137.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.7 | 98.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.23 | 59.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.36B | ||
| ARGX | ARGENX SE - ADR | 77.17 | 43.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.69 | 38.66B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.43B | ||
| NTRA | NATERA INC | N/A | 22.05B | ||
| BIIB | BIOGEN INC | 8.56 | 20.10B |
Related stock screener links
About ACTU
Company Profile
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. The company is headquartered in Fort Worth, Texas and currently employs 10 full-time employees. The company went IPO on 2024-08-13. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Company Info
ACTUATE THERAPEUTICS INC
1751 River Run, Suite 400
Fort Worth TEXAS US
Employees: 10
Phone: 18479864190
ACTUATE THERAPEUTICS INC / ACTU FAQ
What is the stock price of ACTUATE THERAPEUTICS INC today?
The current stock price of ACTU is 6.71 USD. The price increased by 0.9% in the last trading session.
What is the ticker symbol for ACTUATE THERAPEUTICS INC stock?
The exchange symbol of ACTUATE THERAPEUTICS INC is ACTU and it is listed on the Nasdaq exchange.
On which exchange is ACTU stock listed?
ACTU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACTUATE THERAPEUTICS INC stock?
10 analysts have analysed ACTU and the average price target is 27.29 USD. This implies a price increase of 306.63% is expected in the next year compared to the current price of 6.71. Check the ACTUATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACTUATE THERAPEUTICS INC worth?
ACTUATE THERAPEUTICS INC (ACTU) has a market capitalization of 153.79M USD. This makes ACTU a Micro Cap stock.
How many employees does ACTUATE THERAPEUTICS INC have?
ACTUATE THERAPEUTICS INC (ACTU) currently has 10 employees.
What are the support and resistance levels for ACTUATE THERAPEUTICS INC (ACTU) stock?
ACTUATE THERAPEUTICS INC (ACTU) has a support level at 6.63 and a resistance level at 7.1. Check the full technical report for a detailed analysis of ACTU support and resistance levels.
Should I buy ACTUATE THERAPEUTICS INC (ACTU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACTU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACTU, evaluating the profitability, health, valuation and growth aspects
- ACTUATE THERAPEUTICS INC (ACTU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACTUATE THERAPEUTICS INC (ACTU) Sales and EPS estimates to see what analysts future expectations are.
- ACTUATE THERAPEUTICS INC (ACTU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACTUATE THERAPEUTICS INC (ACTU) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACTUATE THERAPEUTICS INC (ACTU) Stock Chart to make your own analysis
- ACTUATE THERAPEUTICS INC (ACTU) Latest news and press-releases to stay up to date.
Does ACTUATE THERAPEUTICS INC (ACTU) stock pay dividends?
ACTU does not pay a dividend.
When does ACTUATE THERAPEUTICS INC (ACTU) report earnings?
ACTUATE THERAPEUTICS INC (ACTU) will report earnings on 2025-11-13.
What is the Price/Earnings (PE) ratio of ACTUATE THERAPEUTICS INC (ACTU)?
ACTUATE THERAPEUTICS INC (ACTU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).
What is the Short Interest ratio of ACTUATE THERAPEUTICS INC (ACTU) stock?
The outstanding short interest for ACTUATE THERAPEUTICS INC (ACTU) is 2.87% of its float. Check the ownership tab for more information on the ACTU short interest.
ACTU Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ACTU. When comparing the yearly performance of all stocks, ACTU turns out to be only a medium performer in the overall market: it outperformed 65.73% of all stocks.
ACTU Financial Highlights
Over the last trailing twelve months ACTU reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -8.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -354.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACTU Forecast & Estimates
10 analysts have analysed ACTU and the average price target is 27.29 USD. This implies a price increase of 306.63% is expected in the next year compared to the current price of 6.71.